Wuxi Biologics Placement - In Time for the Next Lock-Up, Returns Will Probably Not Match Prior Ones

Wuxi Biologics Placement - Probably Not a Surprise to Sell Again when Lock-Up Expires

WuXi Biologics – The Foxconn or Qualcomm of Global CDMO?

Biosimilar Battlefield: U.S. Humira Pushed to 2023

WuXi Biologics IPO Review - An Opportunity to Get Exposure to Biologics in China

Biosimilar Battlefield: Celltrion Forecasts

Biosimilar Battlefield: Samsung Bioepis Forecast

APAC IPOs & Placements

Zhen Zhou, Toh

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

<p>Wuxi Biologics Holdings is selling about US$551m worth of <a href="https://www.smartkarma.com/entities/23679" target="_blank" data-smartkarma-citation="entities:23679:1">WuXi Biologics (Cayman) Inc. (2269 HK)</a> shares. Post share sale, Wuxi Biologics Holdings will still hold 64.3% of Wuxi Biologics.</p><p>The deal scores marginally positive on our framework owing to its undemanding valuation (compared to China and Korea peers) and its strong balance sheet. The company also recently announced that a strong 1H 2017 results, demonstrating strong top-line growth (higher than our estimate in our IPO note). The selldown…</p>

Wuxi Biologics Holdings is selling about US$551m worth of WuXi Biologics (Cayman) Inc. (2269 HK) shares. Post share sale, Wuxi Biologics Holdings will still hold 64.3% of Wuxi Biologics.The deal scores marginally positive on our framework owing to its undemanding valuation (compared to China and Korea peers) and its strong balance sheet. The company also recently announced that a strong 1H 2017 results, demonstrating strong top-line growth (higher than our estimate in our IPO note). The selldown…

無錫バイオロジクスの売却 - ロックアップ期限切れ直後の売却は売却意欲を示唆